Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000898432-23-000193
Filing Date
2023-03-31
Accepted
2023-03-31 16:15:48
Documents
39
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 blac-20221231.htm   iXBRL 10-K 799164
2 exh4-7.htm EX-4.7 70241
3 exh31-1.htm EX-31.1 14011
4 exh31-2.htm EX-31.2 13944
5 exh32-1.htm EX-32.1 6398
6 exh32-2.htm EX-32.2 6715
  Complete submission text file 0000898432-23-000193.txt   3122506

Data Files

Seq Description Document Type Size
7 blac-20221231_cal.xml EX-101.CAL 12061
8 blac-20221231_def.xml EX-101.DEF 157558
9 blac-20221231_lab.xml EX-101.LAB 239415
10 blac-20221231_pre.xml EX-101.PRE 160054
11 blac-20221231.xsd EX-101.SCH 33152
33 EXTRACTED XBRL INSTANCE DOCUMENT blac-20221231_htm.xml XML 194113
Mailing Address 10900 NE 4TH STREET, SUITE 2300 BELLEVUE WA 98004
Business Address 10900 NE 4TH STREET, SUITE 2300 BELLEVUE WA 98004 425-635-7700
Bellevue Life Sciences Acquisition Corp. (Filer) CIK: 0001840425 (see all company filings)

EIN.: 845052822 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-41390 | Film No.: 23787868
SIC: 6770 Blank Checks